Exiqon Licenses LNA Tech to BD for Use in PCR-Based Infectious Disease Dxs

The licensing agreement marks the first time that a company other than Exiqon will use the locked nucleic acid technology to develop diagnostic products.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.